Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
248
datasets available to search
ShareScore release 0.9.0
Dataset results
248 results for “gene editing”
Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs (RNA-seq)
GEO Series GSE168834. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing.
Gene expression profile at single cell level of two TDT patients' PBMCs after gene editing treatment.
GEO Series GSE204688. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing [RNA-Seq]
GEO Series GSE96634. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Transcriptome sequencing of HELZ-null HEK293T human cell line generated by CRISPR/Cas9 gene editing
GEO Series GSE135505. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
CRISPR gene editing and inducible pluripotent stem cell neuronal disease modelling for rare disease diagnosis: EMHM1 genetic variant analysis in Kleefstra Syndrome
GEO Series GSE178646. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Combinatory RNA sequencing analyses reveal RNA editing-dependent and -independent gene regulation by ADAR1 in gastric cancer
GEO Series GSE106874. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6 mediated gene editing in hematopoietic stem cells [BAR-seq]
GEO Series GSE287803. Homo sapiens. 65 samples. Type: Other.
Linking CRISPR/Cas9 double-strand break profiles to gene editing precision with BreakTag
GEO Series GSE223772. Homo sapiens. 220 samples. Type: Other.
Controlling Genetic Heterogeneity in Gene-edited Hematopoietic Stem Cells by Single Cell Expansion
GEO Series GSE232527. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.
Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic proxy for EPO-increasing therapies.
<p>Summary statistics for the genome-wide association study meta-analysis of circulating EPO in 6,127 individuals of European and African American descent. Effect sizes are aligned to allele 1. </p> <p>Description of column names:<br> # Marker - this is the marker name; chromosome:position<br> # Allele1 - the first allele for this marker in the first file where it occurs<br> # Allele2 - the second allele for this marker in the first file where it occurs<br> # Freq1 - weighted average of frequency for allele 1 across all studies<br> # FreqSE - corresponding standard error for allele frequency estimate<br> # MinFreq - minimum frequency for allele 1 across all studies<br> # MaxFreq - maximum frequency for allele 1 across all studies<br> # Effect - overall estimated effect size for allele1<br> # StdErr - overall standard error for effect size estimate<br> # P-value - meta-analysis p-value<br> # Direction - summary of effect direction for each study, with one '+' or '-' per study. Order of the studies is InCHIANTI, BLSA, HealthABC Europeans, PREVEND, HealthABC African Americans<br> # HetISq - I^2 statistic which measures heterogeneity on scale of 0-100%<br> # HetChiSq - chi-squared statistic in simple test of heterogeneity<br> # df - degrees of freedom for heterogeneity statistic<br> # HetPVal - P-value for heterogeneity statistic<br> # TotalSampleSize - overall sample size for that variant in the meta-analysis</p> <p> </p>
Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic proxy for EPO-increasing therapies.
<p>Raw fast-qc files for RNA sequencing analysis of whole <em>EPO</em> gene knock-outs generated through CRISPR-Cas9 gene-editing in HEK-293 cells compared to wild-type controls. </p> <p>Wild-type cell-lines (Empty 1 - Empty 4) were transfected with empty CRISPR-Cas9 constructs to ensure cells were treated under the same experimental conditions. Whole EPO gene knock-outs were generated using a double gRNA approach with CRISPR-Cas9 gene-targeting. Two whole EPO gene knock-out cell-lines were generated (KO-A and KO-B).</p> <p>Library preparation was performed using the TruSeq DNA HT Library Preparation Kit using the 3’ poly-A tail primer Oligo(dT) from Illumina (Illumina, California, USA). RNA Sequencing was performed using the Illumina HiSeq 2500 high-throughput sequencing system (Illumina, California, USA). We resulted in 75 bp paired-end sequences.</p> <p> </p>
An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)
ClinicalTrials.gov study NCT06594094. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
ClinicalTrials.gov study NCT06851767. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Gene Editing as a Therapeutic Approach for Rett Syndrome
ClinicalTrials.gov study NCT05740761. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
ClinicalTrials.gov study NCT05805007. IPD Sharing: NO. Countries: 1. Publications: 0.
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
ClinicalTrials.gov study NCT06647979. IPD Sharing: NO. Countries: 1. Publications: 0.
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
ClinicalTrials.gov study NCT05377307. IPD Sharing: NO. Countries: 1. Publications: 0.
Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease
ClinicalTrials.gov study NCT06112327. IPD Sharing: NO. Countries: 2. Publications: 0.
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders
ClinicalTrials.gov study NCT03855631. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
ClinicalTrials.gov study NCT07226622. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.